| Recruiting | 2/3 | 200 | Europe | Cladribine (MAVENCLAD®), Placebo | Queen Mary University of London, National Institute for Health Research, United Kingdom, Merck Serono Limited, UK, Multiple Sclerosis Society of Great Britain & Northern Ireland, National Multiple Sclerosis Society, Barts & The London NHS Trust | Advanced Multiple Sclerosis, Progressive Multiple Sclerosis | 12/24 | 12/27 | | |
| Active, not recruiting | 4 | 800 | Europe, US | Early Highly Effective Therapies Group, Lemtrada (alemtuzumab), Ocrevus (ocrelizumab), Tysabri (natalizumab), Rituxan (rituximab), Kesimpta (ofatumumab), Briumvi (ublituximab), Escalation Therapies Group, Betaseron (beta interferon), Copaxone (glatiramer acetate), Aubagio (teriflunomide), Extavia (beta interferon), Gilenya (fingolimod), Glatopa (glatiramer acetate), Plegridy (beta interferon), Rebif (beta interferon), Tecfidera (dimethyl fumarate), Avonex (beta interferon), Mavenclad (cladribine), Mayzent (siponimod), Vumerity (diroximel fumarate), Zeposia (ozanimod), Bafiertam (monomethyl fumarate), Ponvory (ponesimod) | The Cleveland Clinic, University of Nottingham | Multiple Sclerosis, Relapsing-Remitting | 07/27 | 09/30 | | |
| Recruiting | 2/3 | 200 | Europe | Cladribine (MAVENCLAD®), Placebo | Queen Mary University of London, National Institute for Health Research, United Kingdom, Merck Serono Limited, UK, Multiple Sclerosis Society of Great Britain & Northern Ireland, National Multiple Sclerosis Society, Barts & The London NHS Trust | Advanced Multiple Sclerosis, Progressive Multiple Sclerosis | 12/24 | 12/27 | | |
